A-shares closed · 港股休市 Quotes 行情 · 25 Sep 17:19 CST
27 Sep 2026 · 21:48 CST Terminal Access 终端入口 →
605369.SH上海证券交易所 · 主板 Main

Gongdong Medical 拱东医疗

Medical Devices 医疗器械
¥17.75−¥0.21 · −1.17%Delayed 行情延迟 · 24 Sep 2026 · 16:14 CST · CNY
Open 开盘
¥17.96
High 最高
¥18.06
Low 最低
¥17.68
Prev Close 昨收
¥17.96
Volume 成交量
151.2万股
Turnover 成交额
¥2,698.8万
Mkt Cap 总市值
¥39亿
P/E 市盈率
69.9×
Recent Activity 近期动态All Filings 全部公告 →

5 significant filings since 30 May 2026: 2 on dividend, 1 on major holder selling and 1 on equity incentive, and 1 other kind. The latest, on 2 Sep 2026: 拱东医疗:5%以上股东集中竞价减持股份计划公告.
自 30 May 2026 起有 5 份重大公告:dividend 2 份、major holder selling 1 份、equity incentive 1 份,另有 1 类。最新一份(2 Sep 2026):拱东医疗:5%以上股东集中竞价减持股份计划公告。

Price History 价格走势

22 trading days 个交易日 · High 最高 ¥17.96 · Low 最低 ¥15.93
16.0016.5017.0017.50
Volume 成交量
327.2万
26 Aug02 Sep09 Sep17 Sep24 Sep

As of 25 Sep 2026 截至2026年9月25日

Assessment 评估

Gongdong Medical, listed in 2020, operates in the medical devices industry. The company reported a decline in attributable net profit from RMB171.6m in 2024 to RMB51.5m in 2025, a drop of 70.0%, while revenue rose slightly by 1.8% to RMB1.14bn. Profit margins weakened, with net margin at 4.5% and ROE at 3.0%. Despite the profit decline, operating cash flow remained strong, at 4.94x net profit in 2025. As of 30 Jun 2026, the balance sheet showed a healthy position, with liabilities to assets at 20.6% and a current ratio of 2.71. In the first half of 2026, revenue and profit both grew, up 5.6% and 8.6% respectively. Ownership is concentrated, with actual controller and largest holder 施慧勇 holding 48.27%.

拱东医疗于2020年上市,属于医疗器械行业。公司2025年归母净利润从2024年的1.72亿元下降至5,150.7万元,同比减少70.0%,而营业收入微增1.8%至11.36亿元。盈利指标走弱,净利率为4.5%,净资产收益率为3.0%。尽管利润下滑,2025年经营现金流与净利润之比达4.94倍,显示现金流状况良好。截至2026年6月30日,资产负债率为20.6%,流动比率2.71,财务结构稳健。2026年上半年营业收入5.88亿元,同比增长5.6%;归母净利润5,469.2万元,同比增长8.6%。实际控制人及第一大股东施慧勇持股48.27%。

What to Watch 关注要点
  • Attributable net profit for the full year 2026
    2026全年归母净利润
  • Operating cash flow to net profit ratio in 2026
    2026年经营现金流与净利润之比
  • Revenue growth in the second half of 2026 compared to the same period in 2025
    2026年下半年收入同比增长情况
  • Changes in 施慧勇's shareholding percentage by the end of 2026
    施慧勇截至2026年末的持股比例变动
  • Inventory days and receivable days as of 31 Dec 2026
    截至2026年12月31日的存货周转天数和应收账款周转天数
  • Next distribution announcement, if any, in 2027
    2027年是否发布新的分红公告
Facts 事实
  • Company: Gongdong Medical 拱东医疗, Shanghai Stock Exchange 605369; industry Medical Devices; listed 16 Sep 2020.
    公司:拱东医疗,上海证券交易所 605369;行业:医疗器械;上市日期:2020年9月16日。
  • Close on 24 Sep 2026 RMB17.75; close on 24 Sep 2025 RMB19.26, RMB19.08 in today's terms; one-year change, adjusted for distributions and share changes -7.0%.
    2026年9月24日收盘价17.75元;2025年9月24日收盘价19.26元(前复权19.08元);一年涨跌幅(复权)-7.0%。
  • 52-week range in today's terms, adjusted for distributions and share changes RMB15.13 to RMB22.29.
    52周区间(前复权)15.13元至22.29元。
  • In the last 12 months 1 trading days closed 9% or more above or below the day before (all days, not only this year). The 1 most recent of them: 23 Jun 2026 +10.0%.
    近12个月共有1个交易日收盘涨跌幅达9%及以上(为全部交易日,不限于今年)。其中最近1个:2026年6月23日 +10.0%。
  • Market capitalisation RMB3.90bn; P/E TTM 69.9; price to book 2.30x.
    总市值39.02亿元;市盈率(TTM)69.9;市净率2.30倍。
  • Revenue 2025 RMB1.14bn; 2024 RMB1.12bn; change +1.8%.
    营业收入2025年11.36亿元;2024年11.15亿元;同比+1.8%。
  • Attributable net profit 2025 RMB51.5m; 2024 RMB171.6m; change -70.0%.
    归属于母公司股东的净利润2025年5,150.7万元;2024年1.72亿元;同比-70.0%。
  • Net profit excluding non-recurring items, 2025 change -63.0%.
    2025年扣除非经常性损益后的净利润同比-63.0%。
  • Basic EPS 2025 RMB0.23; 2024 RMB0.78.
    基本每股收益2025年0.23元;2024年0.78元。
  • Operating cash flow per share 2025 RMB1.15; 2024 RMB1.34; operating cash flow to net profit 4.94x.
    每股经营现金流2025年1.15元;2024年1.34元;经营现金流与净利润之比4.94倍。
  • 2025 gross margin 27.9%; net margin 4.5%; ROE 3.0%.
    2025年毛利率27.9%;净利率4.5%;净资产收益率3.0%。
  • At 30 Jun 2026: liabilities to assets 20.6%; current ratio 2.71; quick ratio 2.40; receivable days 85; inventory days 59.
    截至2026年6月30日:资产负债率20.6%;流动比率2.71;速动比率2.40;应收账款周转天数85;存货周转天数59。
  • Period to 30 Jun 2026 (six months, not comparable with the full years above): revenue RMB588.0m, change +5.6%; attributable net profit RMB54.7m, change +8.6%; operating cash flow per share RMB0.59.
    截至2026年6月30日的报告期(六个月,不可与上述全年数据直接比较):营业收入5.88亿元,同比+5.6%;归母净利润5,469.2万元,同比+8.6%;每股经营现金流0.59元。
  • Ownership: actual controller 施慧勇,施依贝; controlling shareholder 施慧勇; largest holder at 30 Jun 2026: 施慧勇, 48.27%.
    股权:实际控制人:施慧勇,施依贝;控股股东:施慧勇;2026年6月30日第一大股东:施慧勇,持股48.27%。
  • Latest distribution: ex-date 18 Jun 2026, cash RMB0.15 per share.
    最近一次分配:除权除息日2026年6月18日,每股现金0.15元。
  • Aurelian Grade C, score 55.1 of 100, graded within a peer group of 140 companies in its industry; no rank among peers is given.
    金源评级C,得分55.1(满分100),于行业同业140家中评定;未提供其在同业中的排名。
  • Not held for this report: receivable ageing, litigation case amounts, the order book, the auditor's opinion and key audit matters, segment revenue.
    本报告未掌握:应收账款账龄、诉讼案件金额、在手订单、审计意见及关键审计事项、分部收入。